TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing
JCO Precision Oncology · 2024
DOI: 10.1200/po.23.00552 ↗Kurz gefasst
Äquivalenzstudie in der Zeitschrift JCO Precision Oncology, 2024. Verfasst von Stacy Loeb und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, NYU Langone Health, New York, NY. Hauptthemen laut MEDLINE: Genetic Counseling, Prostatic Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Germline genetic testing (GT) is important for prostate cancer (PCA) management, clinical trial eligibility, and hereditary cancer risk. However, GT is underutilized and there is a shortage of genetic counselors. To address these gaps, a patient-driven, pretest genetic education webtool was designed and studied compared with traditional genetic counseling (GC) to inform strategies for expanding access to genetic services. METHODS Technology-enhanced acceleration of germline evaluation for therapy (TARGET) was a multicenter, noninferiority, randomized trial (ClinicalTrials.gov identifier: NCT04447703 ) comparing a nine-module patient-driven genetic education webtool versus pretest GC. Participants completed surveys measuring decisional conflict, satisfaction, and attitudes toward GT at baseline, after pretest education/counseling, and after GT result disclosure. The primary end point was noninferiority in reducing decisional conflict between webtool and GC using the validated Decisional Conflict Scale. Mixed-effects regression modeling was used to compare decisional conflict between groups. Participants opting for GT received a 51-gene panel, with results delivered to participants and their providers. RESULTS The analytic data set includes primary outcome data from 315 participants (GC [n = 162] and webtool [n = 153]). Mean difference in decisional conflict score changes between groups was –0.04 (one-sided 95% CI, –∞ to 2.54; P = .01), suggesting the patient-driven webtool was noninferior to GC. Overall, 145 (89.5%) GC and 120 (78.4%) in the webtool arm underwent GT, with pathogenic variants in 15.8% (8.7% in PCA genes). Satisfaction did not differ significantly between arms; knowledge of cancer genetics was higher but attitudes toward GT were less favorable in the webtool arm. CONCLUSION The results of the TARGET study support the use of patient-driven digital webtools for expanding access to pretest genetic education for PCA GT. Further studies to optimize patient experience and evaluate them in diverse patient populations are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Urology, NYU Langone Health, New York, NY.
- Department of Population Health, NYU Langone Health, New York, NY.
- Perlmutter Cancer Center, NYU Langone Health, New York, NY.
- Department of Surgery/Urology, Manhattan Veterans Affairs, New York, NY.
- Division of Biostatistics and Bioinformatics, Department of Pharmacology, Physiology and Cancer Biology, Thomas Jefferson University, Philadelphia, PA.
- Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA.
ORCID-Profile: Stacy Loeb, Scott W Keith, Heather H Cheng, Amy E Leader, Tatiana Sanchez Nolasco, Christopher Michael Pieczonka, William Kevin Kelly, Nathan Handley, Patrick Johnston Mille, James Ryan Mark, Alexandra McClellan, David R Wise, Veda N Giri
Förderung
- NCI NIH HHS
Zitieren
APA
Loeb, S., Keith, S. W., Cheng, H. H., Leader, A. E., Gross, L., Sanchez Nolasco, T., Byrne, N., Hartman, R., Brown, L. H., Pieczonka, C. M., Gomella, L. G., Kelly, W. K., Lallas, C. D., Handley, N., Mille, P. J., Mark, J. R., Brown, G. A., Chopra, S., McClellan, A., …, & Giri, V. N. (2024). TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing. JCO Precision Oncology. https://doi.org/10.1200/po.23.00552
Vancouver
Loeb S, Keith SW, Cheng HH, Leader AE, Gross L, Sanchez Nolasco T, et al. TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing. JCO Precision Oncology. 2024. doi:10.1200/po.23.00552
BibTeX
@article{Loeb2024,
author = {Loeb, Stacy and Keith, Scott W and Cheng, Heather H and Leader, Amy E and Gross, Laura and Sanchez Nolasco, Tatiana and Byrne, Nataliya and Hartman, Rebecca and Brown, Lauren H and Pieczonka, Christopher Michael and Gomella, Leonard G and Kelly, William Kevin and Lallas, Costas D and Handley, Nathan and Mille, Patrick Johnston and Mark, James Ryan and Brown, Gordon Andrew and Chopra, Sameer and McClellan, Alexandra and Wise, David R and Hollifield, Lucas and Giri, Veda N},
title = {TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing},
journal = {JCO Precision Oncology},
year = {2024},
doi = {10.1200/po.23.00552}
}
EUVIMED